Effects of lignan supplemention vs. placebo on glycemic control and lipid profiles in 68 type 2 diabetic patients (full-analysis-set)

Data are mean±Standard Deviation. BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; apoA1, apolipoprotein A-1; apoB, apolipoprotein B; Lp(a), lipoprotein(a).
*P<0.05 when compared with baseline data.
#Data were not normally distributed. P value was calculated using natural-logarithmically transformed data.